Use of Calibrated Viral Load Standards for Group M Subtypes of Human Immunodeficiency Virus Type 1 To Assess the Performance of Viral RNA Quantitation Tests

ABSTRACT Optimal management of human immunodeficiency virus type 1 (HIV-1) disease requires accurate quantitation of viral RNA concentrations in plasma. Evidence for increasing geographic intermixing of HIV-1 subtypes makes equivalent quantitation of all subtypes essential. The performances of six quantitative viral RNA tests are described, for the first time, with calibrated viral isolates of diverse subtypes.

[1]  D. Richman,et al.  Drug Resistance Patterns, Genetic Subtypes, Clinical Features, and Risk Factors in Military Personnel with HIV-1 Seroconversion , 1999, Annals of Internal Medicine.

[2]  J. Mascola,et al.  Development of Calibrated Viral Load Standards for Group M Subtypes of Human Immunodeficiency Virus Type 1 and Performance of an Improved AMPLICOR HIV-1 MONITOR Test with Isolates of Diverse Subtypes , 1999, Journal of Clinical Microbiology.

[3]  J. Goudsmit,et al.  Design and Evaluation of a Human Immunodeficiency Virus Type 1 RNA Assay Using Nucleic Acid Sequence-Based Amplification Technology Able To Quantify Both Group M and O Viruses by Using the Long Terminal Repeat as Target , 1999, Journal of Clinical Microbiology.

[4]  F. Brun-Vézinet,et al.  HIV-1 subtypes and plasma RNA quantification. , 1999, AIDS.

[5]  J. Baggs,et al.  Impact of HIV type 1 subtype variation on viral RNA quantitation. , 1999, AIDS research and human retroviruses.

[6]  M. Peeters,et al.  Efficiencies of Four Versions of the AMPLICOR HIV-1 MONITOR Test for Quantification of Different Subtypes of Human Immunodeficiency Virus Type 1 , 1999, Journal of Clinical Microbiology.

[7]  D. Levy,et al.  Surveillance for waterborne-disease outbreaks--United States, 1995-1996. , 1998, MMWR. CDC surveillance summaries : Morbidity and mortality weekly report. CDC surveillance summaries.

[8]  T. Quinn,et al.  Determinations of Levels of Human Immunodeficiency Virus Type 1 RNA in Plasma: Reassessment of Parameters Affecting Assay Outcome , 1998, Journal of Clinical Microbiology.

[9]  M. Feinberg,et al.  Report of the NIH Panel to Define Principles of Therapy of HIV Infection and Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Vol. 47/No. RR-5. , 1998 .

[10]  E. De Clercq,et al.  Failure to quantify viral load with two of the three commercial methods in a pregnant woman harboring an HIV type 1 subtype G strain. , 1998, AIDS research and human retroviruses.

[11]  W. S. Clark,et al.  Clinical Comparison of an Enhanced-Sensitivity Branched-DNA Assay and Reverse Transcription-PCR for Quantitation of Human Immunodeficiency Virus Type 1 RNA in Plasma , 1998, Journal of Clinical Microbiology.

[12]  R. Sperling,et al.  Absolute Copy Number and Relative Change in Determinations of Human Immunodeficiency Virus Type 1 RNA in Plasma: Effect of an External Standard on Kit Comparisons , 1998, Journal of Clinical Microbiology.

[13]  T. Fleming,et al.  Intermediate-size trials for the evaluation of HIV vaccine candidates: a workshop summary. , 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[14]  J. Albert,et al.  Subtype‐specific problems with quantification of plasma HIV‐1 RNA , 1997, AIDS.

[15]  T. Leitner,et al.  Most HIV‐1 genetic subtypes have entered Sweden , 1997, AIDS.

[16]  M. Peeters,et al.  Comparative evaluation of three assays for the quantitation of human immunodeficiency virus type 1 RNA in plasma , 1996, Journal of medical virology.

[17]  D. Burke,et al.  HIV-1 genetic diversity. , 1996, AIDS.

[18]  K. Harada,et al.  Direct Observation of Vortex Dynamics in Superconducting Films with Regular Arrays of Defects , 1996, Science.

[19]  John W. Mellors,et al.  Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma , 1996, Science.

[20]  P. Hartigan,et al.  Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. , 1996, The New England journal of medicine.

[21]  J. Mascola,et al.  Detection of diverse HIV-1 genetic subtypes in the USA , 1995, The Lancet.

[22]  R. Hoff,et al.  Trial objectives and end points for measuring the efficacy of HIV vaccines. , 1995, Infectious agents and disease.

[23]  M. Uhlén,et al.  Biological and molecular characterization of subtype D, G, and A/D recombinant HIV-1 transmissions in Sweden. , 1995, Virology.

[24]  J. Mellors,et al.  Quantitation of HIV-1 RNA in Plasma Predicts Outcome after Seroconversion , 1995, Annals of Internal Medicine.

[25]  P. Sharp,et al.  Recombination in HIV-1 , 1995, Nature.

[26]  Groen,et al.  Genomic cloning and complete sequence analysis of a highly divergent African human immunodeficiency virus isolate , 1994, Journal of virology.

[27]  S. Knapp,et al.  A new subtype of human immunodeficiency virus type 1 (MVP-5180) from Cameroon , 1994, Journal of virology.

[28]  Gilcher Ro.  Human retroviruses and AIDS. , 1988 .

[29]  R. Gilcher.  Human retroviruses and AIDS. , 1988, The Journal of the Oklahoma State Medical Association.